ASGR1 and hepatocellular carcinoma: In this sense, the same authors [166] developed an alternative MSN nanosystem consisting of an asialoglycoprotein receptor (ASGPR)-targeting drug delivery system for co-delivery of siVEGF and sorafenib (SO), a multi-kinase inhibitor that can target VEGF for the inhibition of tumor growth and neo-angiogenesis in hepatocellular carcinoma (HCC).